Konstantinos Tryfonidis Selected Research

Cardiotoxicity

1/2017

Cardiac safety, efficacy, and correlation of serial serum HER2-extracellular domain shed antigen measurement with the outcome of the combined trastuzumab plus CMF in women with HER2-positive metastatic breast cancer: results from the EORTC 10995 phase II study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Konstantinos Tryfonidis Research Topics

Disease

16	Breast Neoplasms (Breast Cancer) 01/2022 - 12/2014
11	Neoplasms (Cancer) 11/2023 - 12/2014
2	Triple Negative Breast Neoplasms 11/2023 - 10/2022
2	Neoplasm Metastasis (Metastasis) 01/2021 - 08/2016
2	Infections 01/2018 - 01/2017
1	Pathologic Complete Response 11/2023
1	Carcinoma in Situ 11/2023
1	Heart Arrest (Cardiac Arrest) 01/2018
1	Heart Failure 01/2018
1	Disease Progression 01/2018
1	Hypertension (High Blood Pressure) 01/2018
1	Frailty 01/2018
1	Respiratory Insufficiency (Respiratory Failure) 01/2018
1	Sudden Death 01/2018
1	Pain (Aches) 01/2018
1	Fatigue 01/2018
1	Cardiotoxicity 01/2017
1	Noninfiltrating Intraductal Carcinoma (DCIS) 01/2017
1	Male Breast Neoplasms (Male Breast Cancer) 01/2017
1	Residual Neoplasm 01/2016

Drug/Important Bio-Agent (IBA)

5	Hormones (Hormone)IBA 10/2021 - 01/2016
3	Cyclophosphamide (Cytoxan)FDA LinkGeneric 10/2022 - 01/2018
3	Trastuzumab (Herceptin)FDA Link 01/2022 - 01/2017
2	pembrolizumabIBA 11/2023 - 10/2022
2	pertuzumabIBA 01/2022 - 01/2018
2	Capecitabine (Xeloda)FDA Link 10/2021 - 10/2020
2	Estrogen ReceptorsIBA 01/2017 - 08/2016
1	LigandsIBA 11/2023
1	Doxorubicin (Adriamycin)FDA LinkGeneric 10/2022
1	Carboplatin (JM8)FDA LinkGeneric 10/2022
1	Paclitaxel (Taxol)FDA LinkGeneric 10/2022
1	Epirubicin (Ellence)FDA LinkGeneric 10/2022
1	Vinorelbine (Navelbine)FDA LinkGeneric 10/2021
1	eribulin FDA Link 10/2021
1	tetrachloroisophthalonitrile (Bravo)IBA 10/2021
1	niraparibIBA 10/2021
1	Gemcitabine FDA Link 10/2021
1	AnthracyclinesIBA 10/2020
1	Docetaxel (Taxotere)FDA Link 10/2020
1	Ado-Trastuzumab EmtansineIBA 01/2018
1	taxaneIBA 01/2018
1	Biomarkers (Surrogate Marker)IBA 12/2017
1	abemaciclibIBA 12/2017
1	palbociclibIBA 12/2017
1	ribociclibIBA 12/2017
1	Cyclin-Dependent Kinases (cdk Proteins)IBA 12/2017
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 02/2017
1	Bevacizumab (Avastin)FDA Link 02/2017
1	Monoclonal AntibodiesIBA 02/2017
1	AntigensIBA 01/2017
1	Progesterone Receptors (Progesterone Receptor)IBA 01/2017
1	Interferon Regulatory Factor-7 (Interferon Regulatory Factor 7)IBA 01/2017
1	Phenobarbital (Luminal)FDA Link 01/2017
1	InterferonsIBA 01/2017
1	ErbB Receptors (EGF Receptor)IBA 08/2016
1	Gefitinib (Iressa)FDA Link 01/2016
1	Anastrozole (Arimidex)FDA LinkGeneric 01/2016
1	Keratin-19 (Keratin 19)IBA 12/2014
1	Messenger RNA (mRNA)IBA 12/2014

Therapy/Procedure

9	Therapeutics 11/2023 - 07/2016
8	Drug Therapy (Chemotherapy) 11/2023 - 08/2016
5	Adjuvant Chemotherapy 10/2021 - 12/2014
4	Neoadjuvant Therapy 11/2023 - 01/2016
1	Molecular Targeted Therapy 12/2016
1	Immunotherapy 07/2016